Sanofi ADR (SNY)vsViking Holdings Ltd (VIK)
SNY
Sanofi ADR
$46.78
+0.34%
HEALTHCARE · Cap: $113.93B
VIK
Viking Holdings Ltd
$68.58
-4.20%
CONSUMER CYCLICAL · Cap: $32.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Sanofi ADR generates 619% more annual revenue ($46.72B vs $6.50B). VIK leads profitability with a 17.6% profit margin vs 16.7%. SNY trades at a lower P/E of 20.1x. VIK earns a higher WallStSmart Score of 66/100 (B-).
SNY
Hold49
out of 100
Grade: D+
VIK
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-89.7%
Fair Value
$24.79
Current Price
$46.78
$21.99 premium
Margin of Safety
+36.3%
Fair Value
$120.28
Current Price
$68.58
$51.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Generating 1.6B in free cash flow
Strong operational efficiency at 20.9%
Revenue surging 27.8% year-over-year
Areas to Watch
2.4% earnings growth
ROE of 6.7% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
2.3% earnings growth
ROE of 2.5% — below average capital efficiency
Trading at 28.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.
Bull Case : VIK
The strongest argument for VIK centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.6% and operating margin at 20.9%. Revenue growth of 27.8% demonstrates continued momentum.
Bear Case : SNY
The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.
Bear Case : VIK
The primary concerns for VIK are P/E Ratio, EPS Growth, Return on Equity.
Key Dynamics to Monitor
SNY profiles as a mature stock while VIK is a growth play — different risk/reward profiles.
VIK is growing revenue faster at 27.8% — sustainability is the question.
SNY generates stronger free cash flow (1.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VIK scores higher overall (66/100 vs 49/100), backed by strong 17.6% margins and 27.8% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Viking Holdings Ltd
CONSUMER CYCLICAL · TRAVEL SERVICES · USA
Viking Holdings Ltd engages in the passenger shipping and other forms of passenger transport in North America, the United Kingdom, and internationally. The company is headquartered in Pembroke, Bermuda.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?